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Abstract 
  
 T lymphocytes are cells that play an essential role in both the regulation and 
activation of an immune response. Proper regulation of T cell activation requires two 
costimulatory signals, one from the T cell receptor (TCR)-CD3 complex and the second 
from a surface molecule on an antigen presenting cell (APC). The first signal is 
characterized by the TCR-CD3 complex binding cognate antigen as it is being presented 
on a major histocompatibility complex (MHC) molecule. The second signal involves 
binding of a costimulatory molecule on the surface of a T cell with a counter receptor 
present on the surface of an APC.  
 ICAM-1, the focus of the present work, is a cell surface protein located on T cells 
and functions in adhesion and extravasation of the cell during inflammation. Our lab and 
others have previously published that ICAM-1 is also capable of receiving the second 
signal for T cell activation. In the present work, we elucidated the components of the 
signaling complex formed after stimulation through ICAM-1. The proteins identified thus 
far include mitogen- activated protein kinase (MAPK), cdc2 kinase, CD45, LFA-1, LAT, 
Gads, the Src tyrosine kinase family proteins Lck and Fyn, and the ZAP-70/CD3! 
complex. 
 Since the ICAM-1/LFA-1 interaction is essential for proper T cell function, 
blocking the interaction could be a useful means of regulating improper immune response 
and treating the diseases associated with its dysfunction. Previous studies in our lab using 
peptides to block the ICAM-1/LFA-1 interaction have proven beneficial in treating 
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several autoimmune diseases. Here we sought to test a shorter course of peptide therapy 
and evaluated the treatment in a model for type I diabetes. The peptides not only delayed 
the onset of diabetes in the treated animals, but also drastically reduced the amount of 
infiltration seen within the islets of the pancreas.  
 We also used computational approaches to develop an alternative set of peptides 
with an increased affinity for ICAM-1 and LFA-1 and assessed their effect on T cell 
activation and function. We found that both peptides were able to inhibit MDHC-induced 
T cell adhesion indicating specificity for both ICAM-1 and LFA-1. We also found that 
stimulating with anti-CD3 in the presence of each peptide caused a marked increase in 
proliferation of human T cells. This result suggests that the redesigned peptides are 
capable of acting as a costimulatory signal.
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Introduction 
 
The Immune System. The immune system forms the defense mechanism of a host against 
the outside world. It is comprised of a network of cells and small molecules capable of 
recognizing and responding to an array of perceived danger, such as antigens from 
pathogenic organisms and altered cells that can lead to cancer.  
 The human immune system is divided into two distinct branches: the innate 
immune system and the adaptive immune system. Together these two branches cover the 
spectrum of possible dangers a human could encounter and allow for an appropriate 
response to be mounted. Components from both systems constantly survey the host and 
once a foreign antigen is recognized, an immune response is initiated leading to 
elimination of the foreign agent. 
 Innate immunity is considered nonspecific; it functions in creating physiological 
and anatomical barriers that protect the host in response to any perceived threat. If a 
threat is found, an inflammatory response is initiated that causes vasodilation and 
increased vascular permeability to allow for nonspecific phagocytic cells, such as 
monocytes, macrophages and neutrophils, to enter the inflammatory milieu. The innate 
immune response is considered nonspecific in that it responds in the same way to all 
danger, whether it be a splinter or a bacterial infection. 
 The adaptive immune response is responsible for the specificity associated with 
immunity. This system recognizes and responds to specific foreign antigens present on 
organisms. The success of the adaptive response is predicated on the ability of the system 
to distinguish ‘self’ from ‘non-self’ and to create an amplified response to antigens 
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previously encountered allowing for immunological memory. Cells that participate in 
adaptive immunity include T lymphocytes (T cells), B lymphocytes (B cells) and antigen-
presenting cells (APCs). 
 
T cells. The cells that help to initiate the adaptive immune response to a foreign organism 
are T cells. T cells are named as such because they develop in the thymus. Although they 
originate in the bone marrow as thymic precursors, they eventually migrate to the thymus 
where they mature as thymocytes. Thymocytes express several cell surface proteins, 
including two essential proteins collectively termed the T cell receptor (TCR). Each TCR 
is capable of interacting with only one unique antigen (cognate antigen). The subunits of 
the TCR (!/") are supported by a cluster of accessory proteins collectively termed the 
CD3 complex. The entire CD3 complex includes ##, $% and %& dimers in additional to the 
!/" subunits of the TCR itself. These accessory proteins function for both stability and 
signal transduction.  
 The adaptive response is initiated upon binding of the T cell receptor (TCR)-CD3 
protein complex to its cognate antigen present on the major histocompatibility complex 
(MHC) on the surface of an antigen-presenting cell. This signal coupled with a 
costimulatory signal (described below) lead to both T cell activation and secretion of 
soluble factors that activate other immune system components. This interaction between 
the TCR and cognate antigen provides both specificity and the first signal for T cell 
activation, however this signal alone is not enough to drive full activation. A second 
signal is also required to prevent the T cell from becoming anergic and provides the 
necessary co-stimulation required for differentiation. The second signal is also delivered 
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intercellularly between the T cell and the APC, however it does not require the presence 
of cognate antigen to occur. Once both signals have transpired, the T cell differentiates to 
an effector cell that secretes cytokines to direct further cell activation and mount an 
effective immune response. 
 The study of signaling through a cell surface receptor can be done in vitro through 
stimulation with an antibody specific for that molecule. Binding of the antibody to the 
receptor mimics the natural binding between a ligand and the receptor and can initiate 
signaling. Antibodies against CD3 have been widely used due to the ability of the 
antibody to induce signaling events normally associated with TCR engagement (1,2).  
 
Costimulatory molecules. The traditional second signal protein present on a T cell, CD28, 
interacts with its counter receptor, B7, on the surface of an APC leading to clonal 
expansion, interleukin-2 (IL-2) secretion, and memory cell development. While CD28 
has been the most well characterized signal, several other costimulatory molecules also 
have been identified including CD2, CD45, CD5 and the adhesion molecules LFA-1 and 
ICAM-1 (3-9).  
 The costimulatory molecule focused on in the present work, ICAM-1, can also act 
as the second signal comparable to CD28 and results in greater proliferation, greater 
protection from apoptosis and more T cells exhibiting a memory phenotype as compared 
to stimulation through LFA-1 (10-12). Upon ICAM-1 stimulation, generation of a Th1 
subset is seen as well as induction of IL-2 transcription and secretion, expression of the 
activation marker CD69, and activation of phosphotidylinositol-3-kinase (PI3K) (11). 
Moreover, co-stimulation through ICAM-1 has been shown to initiate kinase activity as 
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well as inactivation of cdc2 kinase, suggesting the ICAM-1 also plays a role in cell cycle 
regulation (13). 
 
Adhesion molecules. Adhesion molecules are cell surface proteins that mediate the 
binding of cells through receptor-ligand interactions. Adhesion molecules are essential to 
biological events such as migration of leukocytes, hematopoesis and activation (14,15). 
The two adhesion molecules focused on in the present work are leukocyte function 
associated antigen-1 (LFA-1 or CD11a) and intercellular adhesion molecule-1 (ICAM-1 
or CD54). 
 
Integrins. Integrins are cell surface proteins that serve to anchor intercellular interactions 
such as cell:cell contact, development and cell migration (14). Integrins are heterodimeric 
glycoproteins composed of an ! and " subunit that are noncovalently linked. The 
integrins are divided into subfamilies based upon the " subunit. There are currently 18 ! 
subunits identified and 8 " subunits that can form some 24 unique integrins through 
different combinations (16). While there are 8 different subfamilies of integrins, the focus 
of work is on LFA-1, a member of the "2 integrin family.  
 "2 integrins are expressed only on lymphocytes. There are 4 known ! subunits that 
interact with the "2 subunit (CD18) to form the integrins !L/"2 (LFA-1/CD11a), !x/"2  
(CD18/CD11c), !m/"2  (MAC-1/CD11b), and !D/"2 (CD11d). The ligands of the "2 
integrins include the blood proteins heparin and fibrinogen, tissue-associated proteins 
such as PSCD1, GNBL2L1 and FHL2 and the adhesion molecules ICAM-1, ICAM-2, 
ICAM-3, ICAM-4 and ICAM-5 (17-21). 
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Leukocyte function associated antigen-1. LFA-1 is a "2 integrin expressed on all 
leukocytes whose ligands include ICAM-1, ICAM-2, ICAM-3, ICAM-4 and ICAM-5 
(22). Interactions between LFA-1 and a ligand are the result of both the level of 
expression and the affinity for each ligand.  Although ICAM-1 is not normally expressed 
at high levels on the cellular surface, ICAM-1 expression is inducible (as described 
below) and has an increased affinity for LFA-1 over ICAM-2 and ICAM-3 (23). The 
affinity of LFA-1 for a ligand can be upregulated through TCR stimulation and can be 
induced by stimulation through ICAM-3 and by low-affinity binding of ICAM-1 (24-27). 
 LFA-1 is the major mediator of cell-cell interactions within the immune system and 
alternations in avidity and affinity for a ligand contributes to the interaction (23). In 
addition to the role LFA-1 plays in adhesion, LFA-1 also functions as a costimulatory 
molecule. Stimulation through LFA-1 using either ligand or antibodies against LFA-1 
results in the hydrolysis of PIP2 and stimulation of intracellular Ca2+ in lymphocytes as 
well as tryrosine phosphorylation of the signaling intermediate Vav (28, 29). Stimulation 
through LFA-1 also turns on important transcription factors such as NF-AT, AP-1 and 
NF-'B that aid in T cell proliferation (28, 30-32). 
 
Immunoglobulins and intercellular adhesion molecule-1. ICAM-1 is a member of the 
immunoglobulin superfamily. Immunoglobulins are glycosylated transmembrane proteins 
that aid in adhesion and cell survival. ICAM-1, also termed CD54, exists as a monomer, 
however non-covalently dimerizes upon stimulation (33). The levels of ICAM-1 
expression on cells vary; ICAM-1 is highly expressed on dendritic cells, but expressed at 
low levels on T cells (34, 35). However, ICAM-1 expression can be upregulated by 
! (!
inflammatory cytokines such as IFN-$ and TNF-! (36). 
 
ICAM-1/LFA-1 interaction. The ICAM-1/LFA-1 interaction is traditionally associated 
with extravasation, or migration of leukocytes from the bloodstream into a tissue during 
inflammation. This process is accomplished in four distinct steps: rolling, activation, 
adhesion and diapedesis (Figure 1.1). Rolling occurs when selectins of the surface of a 
leukocyte bind to several proteins on the surface of endothelial cells. This low-affinity 
interaction serves to slow the travelling cell enough so that the cell can respond to stimuli 
such as chemokines and slow down enough for a high-affinity interaction to occur. The 
high-affinity interaction allows for the activation and adhesion steps where the binding of 
chemokines induces a conformational change in LFA-1 on the leukocyte surface to the 
activated form. Activated LFA-1 then binds to ICAM-1 expressed on the endothelial cell 
surface thereby arresting the cell on the vessel wall. This complete arrest allows for 
transendothelial migration to then occur where the leukocyte undergoes cytoskeletal 
rearrangement to permit travel between two endothelial cells. 
 
Blocking LFA-1/ICAM-1 as a therapy. Many therapies have been developed that act to 
block the costimulatory signal with varying degrees of success. The absence of the 
second signal causes the T cell to undergo anergy or become apoptotic and thus therapies 
directed at inhibiting an active T cell response often seek to exploit this observation (27). 
Several groups have used the blocking of costimulatory molecules and their counter 
receptors in prevention of allograft rejection, reducing the onset of rheumatoid arthritis 
and insulin-dependent diabetes in mice (37-40). Our lab has developed peptides that 
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block the costimulatory signals normally induced by the interaction between ICAM-1 and 
LFA-1 (Figure 1.2). This blockade prevents the second signal from occurring thus 
causing anergy or apoptosis of the T cell. 
 
The thesis. The dynamic functions of ICAM-1 require extensive further characterization 
in order to fully elucidate its complex regulatory role. The focus of this study is to 
identify the proteins associated with ICAM-1 that form a signaling complex capable of 
intracellular signaling. The proteins that we have identified thus far as associated with 
ICAM-1 include mitogen- activated protein kinase (MAPK), CD45, LFA-1, LAT, Gads, 
cdc2, the Src tyrosine kinase family proteins Lck and Fyn, TCR" and the ZAP-70/CD3# 
complex. Characterization of the ICAM-1 associated signaling complex can yield a 
deeper understanding of the immune response at the molecular level and possibly hold 
further implications in disease related therapy. 
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Chapter 2: 
 
The ICAM-1 Signaling Complex 
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Introduction 
 
The hallmark of T cell signaling is formation of an immunological synapse that 
leads to the stimulation of kinase activity and thus to induction of specific gene 
expression. In an inflammatory environment, ligand recognition in the form of cognate 
antigen causes the migrating T cell to arrest and form a stable contact with the antigen-
presenting cell. The T cell then forms a mature synapse at the site of recognition by 
recruiting receptors and signaling molecules that participate in transduction of the signal 
into the T cell resulting in gene activation.  
The synapse itself serves as a molecular scaffold bringing signaling molecules 
into close proximity to allow for direct interaction between kinases and their target 
proteins. The synapse can be subdivided into sections based on the location of molecules 
within the supramolecular activation cluster (SMAC). The central SMAC (cSMAC) is 
enriched with TCR-MHC complexes, kinases and costimulatory proteins. The peripheral 
SMAC (pSMAC) is where adhesion molecules are located that keep the T cell and APC 
in close contact and allow for prolonged engagement of TCR-MHC and other ligand-
receptor interactions. The distal region of the synapse (dSMAC) contains large, bulky 
proteins that otherwise would interfere with protein-protein interactions of the smaller 
signaling molecules.  
Lipid rafts mediate this T cell signaling event by recruiting and transferring signal 
transduction molecules to the site of TCR engagement and cluster within the site of the 
immunological synapse (41-43). The importance of lipid raft involvement in signaling is 
highlighted by the observation that dispersal of lipid rafts inhibits T cell activation (44). 
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Our lab has previously shown that ICAM-1 is capable of acting as a costimulatory 
molecule, induces association and activation of the signaling kinases MAPK 
(ERK1/ERK2), Lck, ZAP-70 and cdc2 and turns on both IL-2 and c-fos gene expression 
(Figure 2.1). Based on these data, we were interested in determining the components of 
the induced signaling complex upon stimulation through ICAM-1. The work presented in 
this chapter highlights the role that associated proteins play in ICAM-1-induced signaling 
and the potential role ICAM-1 may play in an inflammatory context. Information on 
specific proteins identified later in this chapter is provided below. 
 
Gads. Gads (Grb2-related adaptor protein), like Grb2, is a small adaptor protein 
composed of one SH2 and two SH3 domains. Grb2 and some Grb-2 related proteins have 
been shown to interact with signaling proteins such as SLP-76 and Cbl suggesting that 
Grb2 and its related proteins may couple signaling through the TCR to distinct pathways 
(49,50). Like other Grb2-related proteins, the SH2 domain of Gads has been shown to 
interact in vitro with tyrosine-phosphorylated Shc, however the SH3 domain of Gads 
does not bind to any known SH3 domain targets of Grb2 (48, 51). Gads binds the T cell 
signaling proteins SLP-76 through the SH3 domain and the linker of activated T cells 
(LAT) through the SH2 domain (52). 
 
LFA-1. LFA-1 (lymphocyte function-associated antigen 1) is an integrin that has 
traditionally been associated with adhesion and migration of leukocytes through the tight 
junctions between endothelial cells during extravasation into tissues and has been 
implicated as a costimulatory signal capable of inducing T cell proliferation (53). 
! "'!
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             In the context of signaling and the immunological synapse, LFA-1 mediates cell-
cell interaction between the T cell and antigen-presenting cell (APC) by increasing 
adhesion through LFA-1 interaction with ICAM-1 on the surface of the APC.  TCR 
signaling leads to a rapid increase of LFA-1-mediated adhesion through a conformational 
change in protein structure. This change to the active conformation of LFA-1 leads to 
increased avidity, clustering and affinity for ICAM-1 (54-56). LFA-1 is located in the 
peripheral ring (pSMAC) surrounding the cSMAC in the synapse where it functions as 
the major adhesion molecule involved in synapse formation and also acts to exclude 
CD45 from the synapse (57). 
 
CD45. CD45 is a large protein tyrosine phosphatase that regulates both T and B cell 
receptor signaling. CD45 regulates T cell signaling through association with Src family 
kinases such as Lck and Fyn. The cytoplasmic tail of CD45 has intrinsic phosphatase 
activity and acts to remove inhibitory phosphate groups on Lck and Fyn and therefore 
plays a key role in initiation of T cell signaling.  
Despite the major role CD45 plays in T cell activation, it can also inhibit protein-
protein interactions necessary for successful T cell signaling events to occur due to its 
sheer size. LFA-1 acts to exclude CD45 from the synapse upon TCR engagement so that 
a successful signaling event can occur after CD45 has activated Lck and Fyn (57). If 
CD45 is left dispersed throughout the synapse, both the magnitude and duration of the 
TCR signal may be limited.  
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LAT. The linker for activated T cells (LAT) is small membrane-bound adaptor protein 
that is rapidly phosphorylated by ZAP-70 upon TCR engagement (58). Once activated, 
LAT acts as a scaffolding protein for SH2-domain containing molecules and recruits 
other signaling proteins to the synapse including Vav, PLC$1, PI3K, Grb2, SLP-76, Gads 
and Cbl. The LAT knockout mouse, which shows a complete block in T cell 
development, perhaps best illustrates the importance of LAT involvement in signaling 
(59).  
 
Fyn. Upon antigen recognition, the Src family kinases Lck and Fyn are activated and 
rapidly phosphorylate immunoreceptor tyrosine-based activation motifs (ITAMs) on the 
cytoplasmic tail of CD3#. This phosphorylation event allows for binding of the Src 
homology 2 (SH2) domain-containing protein ZAP-70 that subsequently is 
phosphorylated by Lck. Active Src-family kinases are able to phosphorylate downstream 
targets such as SLP-76 (45), Vav (46) and LAT (47) and are paramount in the initiation 
of signaling cascades involved in T cell activation and proliferation. 
 
Immunoprecipitation and protein blotting studies were performed to identify the signaling 
complex that associates with ICAM-1 when peripheral T cells were stimulated through 
ICAM-1. These studies have identified several intracellular proteins involved in receptor-
mediated lymphocyte activation in response to stimulation through ICAM-1. The 
signaling complex is fully formed between two and four minutes after stimulation and 
disassembly seen within 10 minutes. These results, coupled with specific kinase activity, 
suggest the mechanism by which ICAM-1 participates in T cell activation. The complex 
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identified thus far includes Src family kinases Lck and Fyn, CD3#, TCR", MAPK, cdc2, 
LFA-1, the CD45 isoforms CD45RA and CD45RB, and the adaptor proteins Gads and 
LAT. 
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Materials and Methods 
 
Antibodies and reagents. Hybridomas expressing anti-CD54 (R6.5) and anti-CD11a 
(HB202) were purchased from ATCC (Manassas, VA) and antibodies were purified from 
serum-free medium using protein G affinity chromatography (Amersham). Anti-CD3 
(OKT3) stimulating antibody was purchased from BD Biosciences. Anti-CD28 
(ANC28.1) was purchased from Ancell. Anti-CD45, CD45RA and CD45RB were 
purchased from BioLegend. Anti-Fyn and LAT monoclonal antibodies were purchased 
from Epitomics. Anti-GADS was kindly provided by Dr. Tom Yankee. The cross-linking 
goat anti-mouse antibody was purchased from Biorad Laboratories. Biotinylated cholera 
toxin subunit B (Ctx-B) was purchased from Sigma (St. Louis, MO). Streptavidin-Cy3 
was purchased from BioLegend. 
 
Cell stimulation. Total T cells (20 x 106 cells/mL) were incubated at 37°C with 5 µg/mL 
of anti-ICAM-1. Goat anti-mouse IgG (2 µg/mL) was added 2 minutes later. Cells were 
lysed at indicated times in RIPA lysis buffer [10 mM Tris pH 8.0, 140 mM NaCl, 1% 
Triton X-100, 0.5% deoxycholate (DOC), 0.05% sodium dodecylsulfate (SDS), 100 mM 
NaF, 200 µM sodium orthovanadate, 1 mM phenylmethylsulfonylfluoride, 1 µg/mL 
leupeptide and 1 µg/mL pepstatin]. Lysed cells were incubated on ice for 30 minutes and 
centrifuged at 4°C at 11,000 rpm for 30 minutes. Supernatants were collected and protein 
concentrations were determined by Bradford Protein Assay (BioRad) per manufacturer’s 
instructions. Lysates were stored at -70°C until used. 
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Immunoprecipitation and western blotting. Cell lysates were normalized to the lowest 
protein concentration prior to beginning the experiment. Pansorbin (Protein A-bearing S. 
aureus) was precoated with antibodies by incubating antibodies with Pansorbin for 1 hour 
at 4°C. Lysates were immunoprecipitated with antibody-coated Pansorbin overnight at 
4°C. The resulting immune complexes were washed three times in RIPA buffer without 
DOC and SDS and once in RIPA buffer without any detergent (DOC, SDS or Triton X-
100). Pellets were then resuspended in 2X SDS sample buffer [0.69 M Tris pH 6.6, 11% 
glycerol, 2.2% SDS, 0.71 M "-mercaptoethanol, and 0.028% bromophenol blue] and 
heated at 100°C for 5 minutes. Samples were then subjected to 10% SDS-PAGE. 
 SDS-PAGE gels were transferred to polyvinylidene fluoride (PVDF) membranes 
(Millipore) using a semi-dry electrophoretic transfer apparatus unit (Fisher Scientific) in 
transfer buffer [48 mM Tris, 39 mM Glycine pH 9.2, and 1.3 mM SDS] for 2 hours at 
200 mA. Membranes were blocked using a commercial protein-free blocking buffer 
(Fisher Scientific) for 1 hour at room temperature with gentle agitation. Membranes were 
washed three times in Tris buffered saline plus Tween-20 (TBST) [50 mM Tris pH 7.0, 
150 mM NaCl, and 0.1% Tween-20], incubated with indicated primary antibody for 1 
hour at room temperature with gentle agitation and washed three times in TBST. 
Membranes were incubated with the appropriate secondary antibody for 1 hour, washed 
three times in TBST and incubated with commercial enhanced chemiluminescence 
reagent (GE, Amersham). The resulting blot was imaged using a Kodak Image Station 
4000R imager to visualize protein bands. 
 For each identified protein within the complex, the reciprocal 
immunoprecipitation was also completed to verify the protein-protein interaction. For 
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example, since Gads was precipitated with anti-ICAM-1-coated Pansorbin, another 
immunoprecipitation was performed using anti-Gads-coated Pansorbin and probing the 
resulting blot for ICAM-1.   
 
Fluorescence microscopy. Polystyrene microspheres (Polysciences, Inc.) were coated 
with anti-ICAM-1 ("+!,-./01, anti-ICAM+anti-CD3 (&!,-./01, anti-CD28 ("+!
,-./01+anti-CD3 or mouse IgG1 isotype control overnight. Beads were washed in PBS 
to remove unbound antibody and resuspended at the concentration of #!2!"+(!34567./08!
9:;<5=!>!?4007!@4;4!7=5AB46!@A=C!3AD=ABE05=46FG=2H!ID;!$+!/AB:=47!5=!$(JGK!@57C46!=@A?4!AB!
LHM!5B6!IA246!:7AB-!$8(N!O5;5ID;/5064CE648!PA246!?4007!@4;4!/A246!@A=C!5B=A3D6EF?D5=46!
34567!5=!5!"Q"!>!?400Q3456!;5=AD!5B6!AB?:35=46!&!/AB:=47!5=!$(JG8!G4007!@4;4!7=5AB46!@A=C!
7=;4O=5RA6ABFGE$!ID;!$+!/AB:=47!5=!$(JGK!@57C46!=@A?4!AB!LHM!5B6!64OD7A=46!DB=D!OD0EFSF
0E7AB4!?D5=46!70A647!ID;!$+!/AB:=47!5=!;DD/!=4/O4;5=:;48!M0A647!@4;4!=;45=46!@A=C!M0D@P564!
TUD04?:05;!L;D3471!5B6!7=D;46!5=!%JG!:B=A0!5B50E7A78!VAII4;4B=A50!AB=4;I4;4B?4!?DB=;57=!TVWG1!
5B6!I0:D;47?4B?4!A/5-47!@4;4!5?X:A;46!:7AB-!5!Y4A77!Z2ADO05B!/A?;D7?DO4!5=!%+[!
/5-BAIA?5=ADB8 
 
Statistical analysis. Statistical analysis was performed using GraphPad Prism (GraphPad 
Software). 
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Results 
 
Gads associates with ICAM-1 following stimulation of T cells through ICAM-1. As 
shown in Figure 2.2, immunoblotting was performed as described in the Materials and 
Methods in an attempt to identify an adaptor protein present in the ICAM-1 induced 
signaling complex. After extensive testing of candidate proteins, we were able to identify 
Gads as being constitutively associated with ICAM-1. Table 1 lists all proteins tested and 
found to not be associated with the complex. Preliminary data also indicate that Gads 
may be inducibly associated with ICAM-1, with maximal association 2 minutes after 
stimulation through ICAM-1 (data not shown). 
 
LAT associates with ICAM-1 following stimulation of T cells through ICAM-1. As shown 
in Figure 2.3, immunoblotting was performed as described previously and resulting blots 
were probed with anti-LAT. Similar to the association of adaptor protein, Gads (Figure 
2.2), LAT was also seen to be constitutively associated with ICAM-1 both in 
nonstimulated (lane 1) and ICAM-1 stimulated cells (lanes 2-7). 
 
LFA-1 associates with ICAM-1 following stimulation of T cells through ICAM-1. As 
shown in Figure 2.4, immunoblotting was performed as described previously and 
resulting blots were probed with anti-LFA-1 to assess whether LFA-1 is present in the 
ICAM-1 induced signaling complex. Since LFA-1 is present in large quantities in the 
pSMAC, we expected to either find that LFA-1 would not co-precipitate with ICAM-1 
indicating that the ICAM-1 signaling complex is distinct from the SMACs associated 
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with TCR signaling or present in large numbers within the ICAM-1 complex. We found 
the latter hypothesis to be true as we observed a thick band present at 180 kD indicating 
LFA-1 is associated with the complex. !
 
CD45 associates with ICAM-1 following stimulation of T cells through ICAM-1. As 
shown in Figure 2.5, immunoblotting of total T cells was performed as described 
previously and the resulting blots were probed with a polyclonal antibody against CD45 
recognizing the isoforms CD45RA and CD45RB. Since previous proteins involved in 
TCR-mediated signaling have been identified in the ICAM-1 induced complex, we 
expected CD45 to co-precipitate with ICAM-1. We observed that CD45 is constitutively 
associated with ICAM-1 throughout the duration of the initial signaling event (longer 
than 10 minutes after signaling through ICAM-1). 
 We also looked into the presence of individual isoforms of CD45. As shown in 
Figure 2.6, CD45RA, an isoform associated with naïve T cells, is shown to be associated 
with ICAM-1 at all timepoints. Interestingly, as shown in Figure 2.7, a different isoform, 
CD45RB, is notably absent immediately after stimulation through ICAM-1 (lanes 2-3), 
returning after 2 minutes (lane 4) and remaining associated with the complex thereafter 
(lane 5-7). While CD45 activates Lck by removing an inhibitory phosphate, CD45RB 
interferes with lipid raft localization thereby inferring with the activation state of Lck. 
 
Fyn associates with ICAM-1 following stimulation of T cells through ICAM-1. 
Immunoblotting was performed as described previously and the resulting blots were 
probed with anti-Fyn. Since Dr. Chintana Chirathaworn identified Lck as being involved 
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in the signaling complex, we hypothesized that Fyn would also be associated since both 
Src family kinases are involved in TCR-mediated signaling. As shown in Figure 2.8, Fyn 
associates with the complex 2 minutes after initial stimulation and leaves the complex by 
4 minutes. The kinetics that Fyn exhibits is identical to those observed for Lck. 
Interestingly the band that corresponds to the apparent molecular weight of Fyn is 
consistently dim which may indicate a weak association with the signaling complex 
although Fyn is traditionally pale in this type of western blot. 
 
ICAM-1 stimulation clustered lipid rafts to the site of engagement. Antibody-coated 
beads were incubated with fixed and biotinylated-CtxB stained Jurkat cells for 5 minutes 
and counterstained with streptavidin-Cy3 to visualize lipid rafts. The non-toxic " subunit 
of Cholera toxin binds to the ganglioside GM1 present in rafts and allows for imaging of 
the location of lipid rafts on the surface of cells. As shown in Figure 2.9, antibody 
stimulation using anti-ICAM-1 (C and D), anti-ICAM-1+anti-CD3 (E and F) or anti-
CD28+anti-CD3 (G and H) coated beads resulted in polarization of lipid rafts toward the 
antibody-coated bead.  
The percentage of T cell:bead conjugates with lipid raft polarization was 
quantified for both ICAM-1 alone (Figure 2.10) and for anti-CD3+anti-ICAM-1 and 
anti-CD3+anti-CD28 (Figure 2.11) as compared to the isotype control. 
 
Previous studies and experiments described in this chapter have identified several 
intracellular proteins involved in receptor-mediated lymphocyte activation in response to 
stimulation through ICAM-1. The complex identified thus far includes Src family kinases 
! %+!
Lck and Fyn, CD3#, TCR", MAPK, cdc2, LFA-1, the CD45 isoforms CD45RA and 
CD45RB, and the adaptor proteins Gads and LAT. 
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Discussion 
 
As detailed in Chapter 1, ICAM-1 signaling has been associated with 
rearrangement of the actin cytoskeleton, temporary cell cycle arrest and intracellular 
calcium release following activation. The pathways activated by ICAM-1 signaling 
remain poorly understood and of great interest in our lab. Dr. Chintana Chirathaworn 
previously demonstrated that ICAM-1 stimulation leads to transient phosphorylation and 
inactivation of cdc2 kinase, as well as the association of Mitogen Activated Protein 
(MAP) kinases ERK1 and ERK2, ZAP-70 and the Src family kinase, Lck. Chintana 
observed that the TCR signaling intermediate ZAP-70 is phosphorylated upon ICAM-1 
engagement. Additional work has also shown that Lck is activated shortly after ICAM-1 
triggering, with maximal phosphorylation observed by 2 minutes. ERK1 and ERK2 also 
were shown to become activated following ICAM-1 stimulation. 
In addition to the experiments showing kinase activation by ICAM-1 stimulation, 
Chintana also observed involvement of the TCR, CD3# chain, MAP kinases (Figure 2.1). 
Additional work detailed in this chapter has further expanded our knowledge of the 
complex to include CD45RA, CD45RB, LFA-1, Fyn and the adaptor proteins LAT and 
Gads (Figure 2.12).  
Previous work done in the lab to identify an adaptor protein capable of mediating 
the ICAM-1 induced signaling complex was largely unsuccessful. Adaptor proteins are 
commonly found in signaling complexes and directly couple signaling proteins to each 
other. Adaptor proteins usually lack enzymatic activity, but contain SH2 and/or SH3 
domains that allow for protein-protein interaction. SH2 domains recognize specific
! &+!
! &"!
! &#!
tyrosine phosphorylated proteins and are highly conserved. Like SH2 domains, SH3 
domains are highly conserved, present in a variety of signaling molecules and recognize 
proline-rich sequences.  
Common adaptor proteins involved in T cell signaling such as Shc, Grb2, SLP-76, 
Cbl and Sos were not observed in immunoprecipitation experiments upon stimulation 
through ICAM-1 (Table 1). Dr. Jake Kohlmeier hypothesized that a lack of adaptor 
protein may be attributable to the possibility that proteins involved in the ICAM-1 
signaling complex are not associated through direct protein-protein interactions, but 
brought into close proximity by lipid rafts. While lipid rafts play a major role in bringing 
together signaling molecules, it appears that the ICAM-1 signaling complex is at least in 
part mediated by protein-protein interactions involving the adaptor protein Gads. 
Gads has been shown to interact specifically with SLP-76 via the SH3 domain 
and LAT via the SH2 domain. While SLP-76 is a substrate of ZAP-70 and is actively 
involved in TCR-mediated signaling, it was not present in the ICAM-1 complex. The 
absence of SLP-76 as well as the absence of many other traditional proteins involved in 
TCR signaling (Table 1) coupled with the presence of active kinases may indicate that 
ICAM-1 signaling is mediated by a novel complex. While this tends to be the favored 
hypothesis, it also is possible that ICAM-1 signaling may drag CD3-associated signaling 
intermediates into the rather large complex unintentionally. This seems unlikely though 
given the specific activation of kinases and their transient association with the complex. 
The presence of LFA-1 in the complex indicates that supramolecular activation 
clusters, specifically the pSMAC, may be involved in ICAM-1 mediated signaling. LFA-
1 would be expected to associate given the major role the molecule plays in mediating 
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cell adhesion during signaling. The presence of LFA-1 would be necessary to allow for 
both a strong and prolonged interaction between two communicating cells.  
While LFA-1 was shown to co-precipitate with anti-ICAM-1 (Figure 2.4), the 
possibility exists that its presence in the complex is due to protein-protein interactions on 
the surface and not because of a direct association with the complex. Testing of the 
ability of LFA-1 and ICAM-1 to interact with each other on the surface of the same cell 
is of some interest in our lab and future work on this may shed further light on LFA-1 
presence within the complex.  
Because LFA-1 co-precipitated with ICAM-1 as well as other major cell signaling 
proteins like Lck, we expected CD45 to also be present in the complex. Since several 
isoforms of CD45 exist, we looked into the possibility that different isoforms may have 
differing roles within complex formation. Blots were probed with CD45RA, the isoform 
associated with naïve T cell populations, and CD45RB, a lesser known isoform the 
presence of which negatively regulates lipid raft formation (60). CD45RA was seen to be 
associated with ICAM-1 at all timepoints as seen in Figure 5, however CD45RB is only 
associated with ICAM-1 prior to stimulation and after 2 minutes (Figure 2.7). The RB 
isoform is notably absent immediately after stimulation during the crucial initial signaling 
events. While CD45 is known to activate Lck by removing an inhibitory phosphate, 
CD45RB has been shown to interfere with lipid raft localization and thus the activation 
state of Lck. The timing of CD45RB transient absence from the complex is interesting 
especially when coupled with the timing of Lck and Fyn activation. The timing suggests 
that CD45RB moves out of the complex after initial signaling to allow for the activation 
of Lck seen at 2 minutes. It also is intriguing that the disappearance of active Lck from 
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the complex coincides with the reappearance of CD45RB. Future studies into the direct 
association of Lck and CD45RB in the context of ICAM-1 signaling should be examined. 
The polarization of lipid rafts is thought to be requisite for successful T cell 
activation as demonstrated by the observation that dispersal of lipid rafts inhibits full 
activation (44). In Figure 2.9, stimulation through ICAM-1 alone caused lipid rafts to 
coalesce near the antibody-coated bead suggesting that signaling through ICAM-1 may 
promote synapse formation by directing lipid rafts and their associated signaling 
molecules toward the site of cell contact. As shown in Figure 2.10, the increase in the 
percentage of cell:bead conjugates with lipid raft polarization upon stimulation with anti-
ICAM-1 was statistically significant when compared to the isotype control. This indicates 
that the lipid raft polarization seen is a direct consequence of signaling through ICAM-1 
and not simply a non-specific antibody interaction. 
As expected, addition of anti-CD3 to ICAM-1 or CD28 coated beads dramatically 
increased the percentage of conjugates showing raft polarization (Figure 2.11). It should 
also be noted that while ICAM-1 alone can induce polarization of lipid rafts, the addition 
of anti-CD3 increases the percentage to that seen with anti-CD3 and the traditional 
costimulatory molecule, CD28. While the lab has published and extensively studied the 
role of ICAM-1 as a costimulatory molecule, the ability of ICAM-1 to induce lipid raft 
formation to the same extent as CD28 further advances the importance ICAM-1 has in 
signaling.  
While the hallmarks of a traditional signaling event have been well characterized 
regarding the signaling complex associated with ICAM-1, the evolutionary reasoning for 
the complex dynamics remains elusive. Our working hypothesis centers around the idea 
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that ICAM-1 functions to nucleate a complex termed “signal zero” by our lab. As a 
specific T cell searches for its cognate antigen, the ICAM-1 signaling complex keeps 
important signaling molecule ready to fire immediately upon binding of the TCR to 
antigen presented on MHC. If the T cell samples non-cognate antigen presented on MHC, 
the once ready-to-fire complex disassociates and the TCR moves on to sample other 
peptide:MHC complexes on the cell and eventually detaches and moves on to the next 
APC. If the T cell binds cognate antigen, the complex can immediately coalesce lipid 
rafts containing the necessary signaling molecules to induce full activation and allows for 
an immediate response to the foreign antigen. While the data supports this model, we 
have yet to determine a definitive way to test the “signal zero” hypothesis. Identification 
of cdc25 within the complex, the phosphatase that inactivates cdc2, as well as functional 
studies looking at cdc2 activity upon CD3 stimulation are planned. These and other future 
studies within the lab will no doubt focus on ways to determine the evolutionary 
significance of the ICAM-1 induced signaling complex. 
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Chapter 3: 
 
Evaluation of a short dose of therapeutic peptides in treating murine  
type I diabetes in the non-obese diabetic model 
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Introduction 
 
Type I diabetes mellitus, also known as juvenile diabetes or insulin-dependent 
diabetes mellitus, is a chronic autoimmune disorder characterized by the destruction of 
pancreatic "-cells in the islets of Langerhans. The attack on pancreatic "-cells is driven 
by T-cell induced autoimmunity. Self-reactive T cells infiltrate the pancreatic islets where 
they induce "-cell destruction (61). This unchecked attack on pancreatic "-cells leads to 
the inability of the pancreas to adequately control blood glucose levels and the 
development of overt insulitis. 
The non-obese diabetic (NOD) mouse is an experimental animal model for Type I 
diabetes. The strain is polygenic with specific polymorphisms in the gene for interleukin 
2 and the mitochondrially encoded tRNA arginine as well as a deletion of the hemolytic 
complement gene. The strain was originally identified through spontaneous development 
of polyuria and glysuria by a female cataract Shionogi (CTS) mouse (62). The subsequent 
development of the NOD-strain allowed for an approach to not only study the 
pathogenesis of disease, but also opened the door for potential therapeutic approaches 
targeting Type I diabetes to be examined. 
As with any T-cell mediated autoimmune disease, the problem with development 
of an effective therapy is specificity. Current therapeutic approaches for autoimmunity 
focus on a global knockdown of either the entire adaptive immune response through 
immunosuppressants or a knockdown of T cells (including both self-reactive and non 
self-reactive) through targeting specific T cell signaling pathways.  
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The method of choice for specific T cell targeting is through the use of 
monoclonal antibody therapy. While some monoclonal antibodies have proven effective 
in treatment of various diseases, treatment can produce harmful side effects including 
urticaria, leucopenia and potential allosensitization to the antibody itself (64-66). 
Developing a specific treatment for Type I diabetes has proven difficult. Teplizumab, a 
promising humanized anti-CD3 monoclonal, showed preclinical promise in protecting 
remaining "-cells and mediating active disease in mouse models and in in vitro studies 
(63). However, recently the therapy had disappointing results in Phase III clinical trials 
showing no benefit to treatment in patients with Type I diabetes.  
The best approach for therapy would be one where self-tolerance could be 
restored by induction of self-reactive T cell anergy or death. This approach would then 
leave the self-tolerant cells intact and able to respond to infection and eliminate only 
those involved in Type I diabetes. Ideally this therapy would also be as specific as a 
monoclonal antibody, but without the harmful side effects. 
The use of short peptides in treatment of autoimmune disorders has shown 
extensive promise in our lab. Dr. Scott Tibbetts developed short peptides derived from 
the ICAM-1 and LFA-1 contact domains that have shown to be effective in treating 
autoimmune arthritis in a collagen-induced arthritis (CIA) model (Table 2). The safety of 
the peptides also was tested and peptides were found to not alter cell viability or number 
even when used at a 2-fold higher concentration.  
The proposed mechanism is based on blocking both adhesion and costimulation 
through LFA-1/ICAM-1 blockade. As detailed in Chapter 1, antigen-specific TCR 
present on a T-cell interacts with antigen being presented by MHC on an APC. This first 
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signal (termed signal 1) provides specificity for the T cell response by initiating T cell 
activation only if the antigen is cognate. In the case of autoimmune disease, the self-
reactive T cells activate when self-antigen is encountered. For full activation to occur, a 
second costimulatory signal (termed signal 2) must be present. As discussed in Chapter 1, 
both proteins targeted by the peptides, ICAM-1 and LFA-1 are capable of acting as 
costimulatory molecules. If signal 1 is delivered, but signal 2 is blocked, the T cell either 
undergo apoptosis or are rendered anergic and unable to function.  
The proposed induction of tolerance by the peptide treatment is based on allowing 
the self-reactive T cell to encounter antigen (in the case of T1D, "-cell specific antigens) 
thus allowing for signal 1, but blocking LFA-1/ICAM-1 second signals rendering the 
cells dead or anergic. 
Dr. Abby Dotson has successfully shown a delay in T1D disease progression 
when treating NOD mice with 14 injections of the peptides administered over the course 
of 4 weeks. A delay in the increase of blood glucose levels as well as an elimination of T 
cell reactivity were seen when animals were treated with 50 µg of each peptide (100 µg 
total). While Abby had success using this course of treatment, we wanted to see if using a 
shortened dosing regimen would be as successful. The following short dose experiment 
was done in collaboration with Dr. Abby Dotson 
In both the CIA and T1D experiments, long courses of treatment with peptides 
were used. Scott treated animals using alternate day injections throughout the entire 8-
week experiments while Abby treated with a 14 injections regimen. Previous work done 
by Isobe et al showed survival of cardiac allografts using a 6-day course of monoclonal 
antibodies to both ICAM-1 and LFA-1 (67). Since we have had success with treatment of 
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T1D using the peptide therapy, we tested the effectiveness of a short dose regimen on 
mediating T1D disease progression. The work presented in this chapter shows the 
effectiveness of treating NOD-mice with a short doge regimen of LFA-1/ICAM-1 
derived peptides. 
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 Materials and Methods 
 
Mice. Female NOD/ShiLtJ mice (Jackson Laboratories) were obtained at 8 weeks of age 
and were housed individually in barrier cages. Animal experiments were performed with 
approval from the University of Kansas Animal Care and Use Committee. 
 
Peptides. Peptides were prepared and cyclized shown in Chapter 2. Cyclized peptides 
were purchased from American Peptide Company. Lyophilized peptides were stored 
desiccated at -20oC until use. Immediately prior to use, peptides were resuspended in 
normal saline at 1µg/µl.  For i.v. injections, 50 µl c-IE-L and 50 µl cLAB-L were mixed 
immediately prior to injection. 
 
Peptide therapy and diabetes monitoring. Fasting blood glucose levels (BGL) were 
monitored weekly prior to treatment using the OneTouch Ultra 2 glucometer and 
OneTouch Ultra Blue test strips (LifeScan). Fasting levels were determined by removing 
food 2 h before each BGL reading. Saline and therapeutic peptides were injected at 48 h 
intervals beginning at 12 weeks of age until 14 weeks of age. Peptide treated mice 
received a total of 7 injections over the course of 2 weeks. Mice were considered diabetic 
after two consecutive BGL readings >250 mg/dL. When mice were sacrificed due to 
severity of disease, a BGL of 600 mg/dL was used thereafter in the calculations for those 
mice.  
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Pancreas imaging. Pancreata were harvested from treated or control mice and paraffin-
embedded for sectioning. 10 µm planar slices were cut, placed on slides and stained with 
hematoxylin and eosin. Pancreas sections were photographed using a Zeiss Axioscope 
photomicroscope at 40X magnification. 
 
Scoring of islets and the stages of islet destruction. Hematoxylin and eosin stained 
images of pancreatic islets were observed and analyzed for insulitis. All islets identified 
were photographed and the resulting images were scored for islet infiltration as described 
previously (69). Briefly, Pre-insulitis is characterized by no infiltration of leukocytes into 
the islet. Peri-insulitis is characterized by margination of leukocytes along the outside of 
the islet and is indicative of the early stages of infiltration. Intra-insular insulitis is 
characterized by a later stage of infiltration where the majority of the islet has been 
infiltrated with leukocytes. Complete islet destruction is characterized by the complete 
infiltration of the islet by leukocytes (Figure 3.1). 
 
Adoptive transfer. Spleens were harvested from control or peptide treated NOD mice at 
22.5 weeks of age, minced and repeatedly pressed with a 1cc syringe plunger through a 
sterile 70 µm nylon mesh cell strainer.  Erythrocytes were cleared by a five-minute 
incubation of the cell suspension in ACK lysis buffer (0.15M NH4Cl, 10mM KHCO3, 
0.1mM Na2EDTA, pH 7.2) at 37oC.  The resulting cell mixture was purified using a 
mouse total T cell magnetic separation kit and column (StemSep). After purification, 5 x 
106 total T cells were injected into NOD-SCID mice via tail vein injections. Blood 
glucose levels were monitored weekly for 6 weeks post adoptive transfer (Figure 3.2). 
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Statistical analysis. Statistical analysis was performed using GraphPad Prism (GraphPad 
Software). 
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Results 
 
Short dose regimen of peptide caused a delay in the incidence of diabetes. Mice were 
acquired at 8 weeks of age with an average BGL of 96 mg/dL. Glucose levels were 
monitored weekly until mice were 12 weeks of age and mice were randomly assigned to 
either saline or peptide treated groups (n=5 mice per group). The average BGL of each 
group was roughly 110 mg/dL. The increase in blood glucose levels at this age correlates 
with the observation that insulitis begins to occur as early as 3-4 weeks of age and the 
pancreatic insulin content begins to decrease at 12 weeks of age (68). We determined that 
the mice were in the initial stages of diabetes onset. 
 Once the groups were established, mice were injected with either normal saline or 
a combination of cIE-L and cLAB-L for a total peptide dose of 100 µg per injection at 48 
hour intervals. Blood glucose levels were measured at each injection and monitored 
weekly for an additional 12 weeks after the course of treatment was initiated. As shown 
in Figure 3.3, mice receiving the saline injections exhibited an elevated BGL starting as 
soon as treatment was stopped and became overtly diabetic (BGL >250 mg/dL) within 3 
weeks after cessation of therapy (dashed line). In contrast to the saline control mice, the 
peptide treated mice never developed an increase in the blood glucose levels even past 80 
days post therapy initiation (solid line). 
 
Islets of mice receiving peptide treatment show a reduction in leukocyte infiltration. Islets 
from mice were stained with hemotoxylin and eosin, quantified and classified according 
to the level of infiltration described in the Materials and Methods. Examples of each 
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stage of infiltration can be seen in Figure 14.  The degree of infiltration was scored and 
the quantification can be seen in Figure 3.4. 22 islets from the saline injection group and 
32 islets from the peptide treated group were imaged and assessed for the degree of 
insulitis. In the saline treated mice, over 60% of the islets were completely destroyed as 
characterized by complete infiltration of the islet by leukocytes. A small percentage of 
the islets were shown to be in the early-middle and middle-late stages of infiltration, peri-
insulitis and intra-insular insulitis, respectively. Only 22% of the islets were scored as 
pre-insulitis, indicating no infiltration had occurred and the islets were healthy and intact. 
 In contrast, the mice treated with the short dose peptide regimen had the majority 
of the islets fall into the pre-insulitis category indicating the vast majority of islets in the 
treated animals were healthy. Only 21% of the short dose treated islets fell into the later 
three stages of peri-insulitis, intra-insular insulitis or complete islet destruction. 
 
Adoptively transferred T cells harvested from short dose treated mice do not induce 
diabetes in NOD-SCID mice. Total T cells were harvested from the spleens of either 
saline or short dose treated mice and injected into NOD-SCID mice. NOD-SCID mice 
lack endogenous T and B cells and therefore do not develop type 1 diabetes as seen in the 
NOD model. Due to the inability of the NOD-SCID model to develop diabetes without 
exogenous T cell transfer, their blood glucose levels remain constant and never increase 
throughout their lifespan (70). As shown in Figure 3.5, NOD-SCID mice that received 
adoptively transferred T cells from saline control NOD mice developed overt diabetes 
within 3 weeks. In direct contrast, the NOD-SCID mice receiving cells from the short 
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dose treated mice did not have an increase in blood glucose level even when monitored 
past 40 days post adoptive transfer. 
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Discussion 
 LFA-1 and ICAM-1 play important roles in the development of autoimmune 
disorders (71). Current treatments targeting these two molecules center around antibody-
based therapy, however given the immunogenic nature of antibodies, alternate therapies 
should be considered. Peptides were developed from the consensus binding sequences of 
both LFA-1 and ICAM-1 and were shown to be effective in blocking intercellular 
adhesion as well as inhibiting human T cell function within the context of a mixed 
lymphocyte reaction (72).  Previous studies of the immunological effectiveness of these 
peptides in mediating rheumatoid arthritis were successful as well as a recent foray into 
type I diabetes. Data presented in this chapter show that treatment of NOD mice with 
only 7 injections ablates disease as compared to saline injected controls. 
 A long dose course of peptide treatment (17 injections) was effective in delaying 
the onset of disease as well as reducing insulitis, ablating antigenic recall and inducing 
death or anergy of auto-reactive T cells (73). The data accumulated throughout the course 
of both the long dose experiment and the short dose experiment presented in this chapter 
suggest that blocking the LFA-1/ICAM-1 interaction with peptides inhibits both T cell 
localization and function. Previous studies targeting LFA-1/ICAM-1 but conducted using 
monoclonal antibodies attributed the reduction of T1D symptoms to the inability of 
lymphocytes to enter islets (74). Our data suggest that the peptides inhibit not only the 
ability of self-reactive T cells to enter islets, but also inhibit T cell activation and function 
as demonstrated by the observation that T cells from treated mice could not respond to 
islet specific antigen in a recall response.  
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Previous studies by other investigators examined blocking specific costimulatory 
molecules in an attempt to inhibit various autoimmune diseases, including T1D. Use of a 
CTLA4Ig fusion protein to interfere with the B7/CD28 pathway proved successful in 
inhibiting disease when administered at 2-4 weeks of age in NOD mice, but was not 
effective after 10 weeks (75). This therapy also did not inhibit insulitis regardless of the 
age of the mice at initial treatment. Combination therapies targeting multiple 
costimulatory pathways have also not been proven to be any more effective than 
blockage of each individual pathway (76). It appears that blocking both T cell activation 
and migration into the islets is key to halting disease progression. 
While the long dose treatment delayed the onset of diabetes as compared to the 
saline control, the peptide treated mice still did develop overt diabetes by the end of the 
study. Interestingly, it appears that decreasing the treatment regimen from 17 to 7 doses 
effectively inhibited the ability of the NOD mice to develop disease (Figure 3.3).  Since 
the studies were not done concurrently, it is difficult to draw specific conclusions. The 
long dose study used larger groups of mice that could account for the differences seen 
between the treatment regimens. It is also possible that we have simply gotten better at 
conducting the experiments with the short dose. Still, while it is possible that the 
difference between studies could account for the differences in the development of 
disease, it is interesting to speculate that a shortened dose of peptide therapy may ablate 
disease completely while a longer dose simply results in a delay of onset. Future studies 
directly comparing both long and short dose treatments using large groups of mice would 
be able to shed light on this question and are planned for the future. 
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The data presented in this chapter show that using a shortened course of peptide 
treatment (7 injections) was as effective as a long dose treatment (17 injections) in 
ameliorating type I diabetes in a mouse model. The short dose treated groups showed 
improvement in both overt diabetes as seen in the consistently low blood glucose levels 
as well as on the cellular level as demonstrated by the reduction of lymphocyte 
infiltration into the islets. Future projects examining the kinetics of the short dose therapy 
as well as looking into the possibility of "-cell regeneration after the cessation of therapy 
are planned. Assessing the ability of the peptides to function in organ transplant rejection 
as well as other autoimmune disease models have also been proposed and will likely be 
completed in the future. 
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Chapter 4: 
 
Development and evaluation of redesigned LFA-1 and ICAM-1 derived peptides using a 
computational approach 
! )$!
Introduction 
 
As discussed previously, therapies that directly interfere with ICAM-1/LFA-1 
binding have extensive therapeutic potential. While antibodies directed against these two 
molecules have shown promise, the deleterious effects associated with their use rarely 
outweigh the benefit. In an attempt to develop alternate methods of blocking the 
interaction, Dr. Scott Tibbetts developed short peptides targeted against each molecule. 
Each peptide was derived from the binding interface of LFA-1/ICAM-1 and tested for 
both toxicity and effectiveness. While the native derived peptides have shown 
tremendous promise in treating several autoimmune diseases and modulating the immune 
response, we sought to develop using a computational approach an alternate set of 
peptides that bound more tightly to the native protein. Several current therapeutics have 
been born from using a computational approach exploiting the protein-protein 
interactions between molecules to mediate disease. Recently, a structure-based design of 
an amyloid fibril inhibitor showed promise in disrupting fibril formation whose 
accumulation is associated with developing Alzheimer’s disease (77). We hypothesized 
that this approach would enhance the efficacy of the peptides by allowing for a blockade 
of the ICAM-1/LFA-1 interaction that lasted longer than the native peptides thus 
enhancing the effectiveness of the therapy.  
Rosetta is a software package developed to predict protein structure and function 
(79). The program samples conformational space associated with the input structures and 
evaluates the energy changes of the resulting model. The input structures are taken from 
the Protein Data Bank (PDB), which houses the experimentally mapped crystal structures 
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of proteins (80). Once the correct PDB accession number is given, the modeling program 
optimizes both the structure and sequence of the protein.  Rosetta considers every amino 
acid at each position along the protein sequence and outputs an energy value, ((g, for all 
variants. This ((g value correlates to the stability difference between a mutated variant 
and the native, wild-type protein. A higher ((g value therefore represents a protein 
variant that is less stable than its wild-type counterpart. Consequently, a negative ((g 
value would indicate a more stable structure than the native protein. By using Rosetta, we 
were able to design alternate peptides that included two point mutations that were 
computationally predicted as being more stable than the native structure. We tested these 
“redesigned” peptides in in vitro assays of T cell adhesion and function to assay their 
behavior in relation to the native peptides. 
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Materials and Methods 
 
Antibodies and reagents. Hybridomas expressing anti-CD54 (R6.5) and anti-CD11a 
(HB202) were purchased from ATCC (Manassas, VA) and antibodies were purified from 
serum-free medium using protein G affinity chromatography (Amersham). CD4-FITC 
was purchased from BioRad. Anti-CD3 (OKT3) stimulating antibody was purchased 
from BD Biosciences. Anti-CD28 (ANC28.1) was purchased from Ancell. Antibodies 
were used at a concentration of 5 µg/mL. MDHC (methyl-2,5-dihydroxycinnamate) was 
obtained from Toronto Research Chemicals and used at a concentration of 10 µM.  
 
Cell purification and culture. Fresh human tonsil cells or peripheral blood were used for 
the activation experiments. Tonsils were minced in tissue culture PBS [137 mM NaCl, 
2.7 mM KCL, 1.5 mM KH2PO4, 9.6 mM Na2HPO4, 0.7 mM CaCl, 0.5 mM MgCl2, 10 
mM glucose] with 2% fetal bovine serum and pen/strep (50 U/mL each) and cells in 
suspension were separated from tissue using a strainer. Peripheral blood was diluted 1:1 
in TC-PBS. Cell suspensions were layered 3:1 over Ficoll (Pharmacia) and centrifuged at 
1800 rpm for 30 minutes. The mononuclear cell layer was then isolated and rinsed with 
TC-PBS. The T cells were then separated using the E-rosette method (81). Freshly 
isolated cells were rested overnight at 37°C prior to experimentation.  
For tonsillar T cells, greater than 95% of T cell isolates were positive for the T 
cell surface marker CD3, as assessed by flow cytometry. For peripheral T cells, greater 
than 98% of T cell isolates were positive for CD3. Culture medium for fresh T cells and 
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Molt-3 was RPMI 1640 supplemented with 10% FBS, 50 U/mL each of pen/strep and L-
glutamine (2 mM).  
 
Redesigned peptides. Redesigned peptides were computationally prepared using 
Rosetta’s specificity switch code. The LFA-1/ICAM-1 crystral structure (PDB accession 
# 1MQ8) was used as the input structure. Each resulting variant and the associated free 
energy change was stored and only those variants located within the binding interface 
(residues 26-35 on ICAM-1 and residues 237-246 on LFA-1, correlating to the native 
peptide sequence location) were considered (Figure 4.1). Of the mutations within those 
sequences, the predicted structure with the mutation having the lowest ((g value was run 
through the specificity switch program again to obtain a second stabilizing mutation by 
again choosing the mutation with the lowest associated ((g value. From the predicted 
and calculated structures, the redesigned peptides were constructed (Table 3). The 
predicted structure of the LFA-1-derived redesigned peptide (rcLAB-L) is shown in 
Figure 4.2 and the predicted structure of the ICAM-1-derived redesigned peptide (rcIE-
L) is shown in Figure 4.3. 
Cyclized redesigned peptides were purchased from American Peptide Company. 
Lyophilized peptides were stored desiccated at -20oC until use at which time they were 
resuspended in culture medium at the indicated concentrations. 
 
Homotypic adhesion assay. For antibody-stimulated samples, 96-well plates were coated 
with anti-CD3 for 3 hours at 37 oC and washed extensively with PBS to remove any 
unbound antibody. Molt-3 T cells were then added to the plate at a concentration of 105
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cells/well for 6 hours alone, with MHDC, or with MDHC plus varying concentrations of 
peptides. For analysis, three random fields of each sample were photographed at 40X 
magnification. The number of clumped cells was indirectly estimated as follows. The 
number of non-clumped cells in the nontreated plates was used as the baseline value. The 
number of clumped cells in the treated samples was approximated by counting the 
nonclumped cells in each of the fields and subtracting that number from the mean number 
of cells per field in the nontreated control.  
 
Proliferation assay. Antibodies were attached to plastic by incubation for 3 hours at 37 oC 
and washed extensively with PBS to remove any unbound antibody. Fresh human T cells 
were stained with CFSE and plated at a concentration of 2 x 106 cells/mL in the absence 
or presence of 250 µM of peptide. Cells were incubated for 3 days at 37 oC, harvested and 
proliferation quantified by flow cytometry.  
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Results 
 
Both redesigned peptides inhibit MDHC-induced homotypic adhesion. LFA-1/ICAM-1-
dependent homotypic adhesion of T cells is a reliable way for screening the ability of a 
compound to interfere with the interaction between LFA-1 and ICAM-1. As discussed in 
Chapter 1, our lab previously has published that the tyrosine kinase inhibitor MDHC can 
induce homotypic adhesion of Molt-3 cells and that this adhesion is a direct result of the 
ICAM-1/LFA-1 interaction (82).  
As shown in Figure 4.4, both peptides were capable of inhibiting MDHC-induced 
homotypic adhesion. In Panel B, treatment of cells with MDHC resulted in the ability of 
the cells to form large aggregates of between 5 and 50 cells throughout the culture. In 
Panel C, treatment with rcIE-L at the same time as MDHC inhibited the ability of the 
cells to form clumps completely, with no clumps of more than 3 cells observed 
throughout the culture. This suggests that rcIE-L is capable of binding to LFA-1 and 
preventing the ICAM-1/LFA-1 interaction. Treatment with rcLAB-L showed similar 
results (Panel D) indicating that it is capable of binding to ICAM-1 and preventing the 
ICAM-1/LFA-1 interaction also.  
To quantify the ability of the peptides to inhibit adhesion, the number of clumped 
cells per field was indirectly estimated as described in the Materials and Methods section 
of this chapter. Figure 4.5 shows that treatment with rcIE-L significantly reduced 
adhesion as compared to the MDHC-treated control. Treatment with rcLAB-L displayed 
similar results as shown in Figure 4.6. 
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rcIE-L inhibition of homotypic adhesion is concentration-dependent. rcIE-L was tested at 
varying concentrations ranging from 1 µM up to 500 µM. As shown in Figure 4.5, 
treatment with rcIE-L significantly inhibited MDHC-induced adhesion in concentrations 
as low as 1 µM. An effective concentration of 24 µM has been previously reported using 
native peptides derived from ICAM-1, but the redesigned rcIE-L peptide was effective at 
inhibiting MDHC-induced adhesion in the lowest concentration tested of 1 µM (83).  
 
rcLAB-L inhibition of homotypic adhesion is not concentration-dependent. rcLAB-L was 
tested at varying concentrations ranging from 1 µM up to 500 µM. Similar to the results 
seen with the ICAM-1 derived redesigned peptide, rcIE-L, treatment with the LFA-1 
derived rcLAB-L significantly inhibited MDHC-induced adhesion in concentrations as 
low as 1 µM. However, the inhibition seen with rcLAB-L does not appear to be 
concentration dependent as illustrated in Figure 4.6. All concentrations tested were 
effective at inhibiting MDHC-induced adhesion. 
 
 rcIE-L enhances proliferation. We tested the effects of the redesigned rcIE-L peptide on 
T cell proliferation induced by anti-CD3. Stimulation through CD3 by the anti-CD3 
antibody mimics the first signal through the T cell receptor that is required for T cell 
activation and proliferation. As a positive control, anti-ICAM-1 or anti-LFA-1 were 
added to anti-CD3 to mimic the second signal also required for full activation. The 
degree of proliferation was determined using CFSE staining. CFSE is taken up by the 
cells and partitioned equally as the cell divides. The resulting cell divisions can then be 
quantified by the amount of CFSE retained by using a flow cytometer. The proliferation 
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index correlates to the cells that have gone through one or more active cell divisions. As 
shown in Figure 4.7, co-culture of cells with rcIE-L enhanced T cell proliferation with 
stimulated with anti-CD3. Treatment with the alternative peptide did not significantly 
enhance proliferation when co-cultured with both anti-CD3 and either second signal-
mimicking antibody.  
 
rcLAB-L enhances proliferation. We also tested the effects of the redesigned rcLAB-L 
peptide on T cell proliferation by anti-CD3. As shown in Figure 4.8, co-culture of cells 
with rcLAB-L enhanced T cells proliferation with stimulated with anti-CD3 to a similar 
degree as both antibody second signals. Treatment with the alternative peptide did not 
significantly enhance proliferation when co-cultured with both anti-CD3 and either 
second signal-mimicking antibody similar to the results seen with rcIE-L. 
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Discussion 
 
While the original goal of redesigning the peptides was to enhance the blockade 
between ICAM-1/LFA-1, we quickly learned that the redesigned peptides functioned in a 
different manner than the native peptides. Dr. Scott Tibbetts performed extensive 
experimentation on the native peptides, IE-L and LAB-L as well as others not located 
within the binding interface. The results from those experiments show that both the IE-L 
and LAB-L peptides were capable of inhibiting MDHC-induced T cell adhesion and were 
unable to stimulate T cell proliferation. It is hypothesized that the native peptides work 
by binding to the target site and physically blocking the interaction between ICAM-1 and 
LFA-1 from occurring. This blockage occurs without the peptide transducing a signal 
through it’s target molecules, as would normally occur upon binding of the two full-
length proteins. 
When testing the redesigned peptides in some of the same assays Scott used, we 
ascertained that the redesigned peptides, rcIE-L and rcLAB-L, were also capable of 
inhibiting MDHC-induced adhesion as did their native counterparts. While both native 
peptides did so in a dose-dependent manner, only one of the redesigned peptides, rcIE-L 
behaved similarly. The LFA-1-derived rcLAB-L was capable of inhibiting MDHC-
induced adhesion in all concentrations tested, but did not do so in a dose-dependent 
manner. Inhibition occurred at the same rate whether the cells were incubated with 500 
µM or 1 µM of rcLAB-L. The differences in dose dependency may be explained by the 
binding states of the proteins. In order for tight binding of the adhesion molecules to 
occur, LFA-1 must be in the open, activated conformation (84). Because of the different 
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states of LFA-1, it is likely that higher concentrations of rcIE-L induce the conformation 
change from the low affinity state to the high affinity form of LFA-1. Conversely, the 
rcLAB-L peptide is likely mimicking the high-affinity, activated conformation of LFA-1 
and therefore the peptide is effective at inhibiting adhesion at even very low 
concentrations. Regardless of the differences in dose-dependence between the redesigned 
peptides, we found that both rcIE-L and rcLAB-L were capable of inhibiting adhesion 
through ICAM-1/LFA-1. 
Since both LFA-1 and ICAM-1 induce intracellular signaling in T cells as 
described in Chapter 1, we investigated the ability of the redesigned peptides to act as 
costimulatory molecules. The native peptides, when used alone or in conjunction with 
CD3 stimulation, were unable to induce proliferation in response to the peptide. This was 
attributed to the fact that the peptides likely have a lower affinity for the target protein 
than do the monoclonal antibodies. Since the redesigned peptides were predicted as 
having a higher affinity for the target protein, we would anticipate that they might also be 
able to transduce a signal and act as a costimulatory molecule themselves. To test this 
hypothesis, we performed proliferation assays. Human T cells were stimulated with anti-
CD3 in the absence or presence of each peptide and proliferation assessed. As shown in 
Figures 24 and 25, both rcIE-L and rcLAB-L induced proliferation to the same level as 
the cells stimulated with monoclonal antibodies to LFA-1 and ICAM-1. This indicates 
that each redesigned peptide is capable of acting as a costimulatory molecule. While 
proliferation is a reliable index of T cell activation, further studies comparing cells 
costimulated with peptides and those using antibodies against ICAM-1 and LFA-1 should 
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be done to verify the signaling cascades turned on by the peptides are the same as those 
activated through antibody-mediated costimulation. 
While the native peptides show promise for use in interventional therapies for 
autoimmune diseases, the redesigned peptides may be of use in preventative applications 
like vaccines. In addition to interventional therapies derived from using a computational 
approach, new advances in vaccine development have also arisen from the use of rational 
design. Vaccines require active T cell proliferation to occur in response to the target 
antigen being introduced. If the T cell response is correctly stimulated by the vaccine 
components, a memory response is generated to the target antigen. If the T cell response 
is not actively engaged, no proliferation occurs in response to the foreign antigen and 
immunity to the target antigen is not established thereby offering no benefit of the 
vaccine.  
Peptide constructs have been developed as a vaccine delivery system that fuses a 
computationally optimized target epitope to a proprietary T cell epitope to activate a T 
cell response (78). This technology uses a computational approach to maximize the 
immune response to a foreign antigen by optimizing the antigen itself. This optimization 
includes introducing conformational restraint, if necessary, as well as fusion of the target 
antigen to a T cell-specific epitope. It is the fusion to the T cell-specific epitope that 
causes proliferation in response to the antigenic target. In contrast, we optimized T cell 
specific peptides and therefore do not require fusion to a T cell-specific epitope. This 
would allow for enhanced T cell activation that is requisite for a beneficial vaccine 
without changing the target antigen. By doing so, the redesigned peptides could be useful 
in vaccines that have a functional epitope mapped, but lack the intrinsic properties to 
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generate an active T cell response. Further testing assessing the toxicity and the 
effectiveness of the redesigned peptides in vaccine delivery needs to be completed using 
animal models. Since the native peptides were shown to not be toxic to cells, we would 
expect both rcIE-L and rcLAB-L to be nontoxic as well since the redesigned peptides 
share 80% homology, however toxicity still needs to be empirically tested.  
The redesigned peptides might also be useful in individuals that are not capable of 
stimulating a T cell response to a vaccine such as those who are immunosuppressed or in 
the elderly population. Pilot studies using T cells harvested from elderly individuals (over 
age 65) showed that peptide treatment with either rcLAB-L or rcIE-L marginally 
enhanced T cell proliferation when also stimulated through CD3 (data not shown), 
however the cells did not stimulate well. Cells stimulated through CD3 and the 
monoclonal antibodies to ICAM-1 and LFA-1 did not proliferate above 20% so it is 
difficult to draw conclusions. Further studies into the effect of the redesigned peptides on 
the elderly population should be done to see their effectiveness on stimulating T cells that 
normally do not stimulate well. 
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